AzTrials
AzTrials

ARDSNCT03546699

Hospital-wide Incidence, Clinical Characteristics and Outcomes of ARDS

An observational study of ARDS and Respiratory Failure, run by University Health Network, Toronto at 4 sites in 3 countries.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

The Acute Respiratory Distress Syndrome (ARDS) impacts one of every four patients requiring mechanical ventilation for respiratory support and carries a mortality rate of 40%. To diagnose ARDS, doctors currently use the Berlin definition, that requires chest radiographs and analysis of oxygenation in the blood… Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
ARDS, Respiratory Failure, Lung Ultrasound
What is being tested?
Estimation of hospital-wide incidence of ARDS
How many people
9,999 participants
Where
4 sitesin 3 countries
Study dates
24 Oct 2018to 15 Oct 2023
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Study population: All adults admitted to the hospital during either of two one-week study periods (winter and summer)

Who may be able to join

  • Hospital admission during the study period
  • Age ≥ 18 years old
  • New onset of hypoxemia (SpO2 < 90% or use of any supplemental oxygen) or, for patients on home O2 treatment, higher than baseline O2 flow needed during the first 7 days of hospitalization.

Who cannot join

  • Patient in the Emergency Department but not formally admitted to the hospital
  • Patient admitted in PACU

Trial locations and contacts

4 sites in 3 countries.

4 sites in 3 countries

Italy2 sites
  • AOU Citta' della Salute e Della Scienza - Molinette

    Torino

  • Ospedale San Giovanni Bosco

    Torino

Other trials in Italy

United States1 site
  • Beth Israel Deaconess Medical Center

    Boston, Massachusetts, 02215

Other trials in United States

Canada1 site
  • University Health Network

    Toronto, Ontario, M5T2S8

Other trials in Canada

About this study

Official title: A Multicenter Prospective Cohort Study of Hospital-wide Incidence, Clinical Characteristics and Outcomes of ARDS - The NITWA ARDS Study

The Acute Respiratory Distress Syndrome (ARDS) impacts one of every four patients requiring mechanical ventilation for respiratory support and carries a mortality rate of 40%. To diagnose ARDS, doctors currently use the Berlin definition, that requires chest radiographs and analysis of oxygenation in the blood (arterial blood gas). These tests are not available in areas of the world with constrained resources and may be unnecessarily invasive. A modification of the Berlin definition, using ultrasound and pulse oximetry (a small device that measures oxygen level non-invasively by clipping to the body, typically a finger), has been recently developed and tested in Kigali, Rwanda.

This study will try to confirm the validity of the Kigali modification initially in Boston and Toronto and subsequently in other hospitals worldwide. If confirmed, this new definition could allow for faster recognition and potentially improved treatment of patients with ARDS and facilitate studies worldwide.

Read more

The purposes of this study are:

  1. To describe clinical characteristics and outcomes of patients diagnosed with ARDS according to the Berlin and Kigali definitions;
  2. To determine how well chest radiograph and ultrasound of the chest are able to define ARDS, in comparison to chest computer tomography (CT).
Read the detailed description

We hypothesize that the hospital-wide incidence of ARDS, as defined by the Kigali modification, is similar in high resource settings (e.g., Boston and Toronto) as compared to the resource-constrained setting of Kigali, Rwanda. We also hypothesize that pulmonary ultrasound is a more sensitive and similarly specific imaging modality for bilateral opacities than chest radiograph, when compared to the reference standard of chest tomography.

We will test these hypotheses in a multicenter prospective cohort study with the following specific aims:

Aim 1: A) To estimate the hospital-wide incidence of ARDS defined according to both the Berlin definition and the Kigali modification, and B) To describe clinical characteristics and outcomes for these patients.

Aim 2: For the subset of patients who have chest CT, to determine the sensitivity and specificity for bilateral opacities of both chest radiographs and chest ultrasound done within 12 hours as compared to the reference standard CT scans.

As a part of the research study, we will perform a pilot study with the specific aim of assessing feasibility of a multicenter study. Criteria that will be used to assess feasibility include:

  1. Number of hospitalised adult patients who fulfill Kigali or Berlin ARDS criteria over the first 7 days post-hospital admission;
  2. Number of hospitalised adult patients who develop hypoxemia as detected on daily screening, during the first 7 days post-hospital admission (% hypoxemic patients/new admissions);
  3. Proportion of recruited patients/eligible patients (see below for eligibility criteria);
  4. Work-load per patient (lung ultrasound scanning time; average data collection time on the first day of hypoxemia);
  5. Proportion of patients with CXR, CT scan and LUS available from the same +/-1 day.

All adults (≥ 18 years old) admitted to the hospital during either of two one-week study periods (winter and summer) will be screened daily for hypoxemia (defined as oxygen saturation < 90%) or use of any supplemental oxygen for a total of 7 days. For the initial feasibility phase, both in-person and electronic administrative records screening will be performed. Depending on the site and the results of the pilot phase, in the multicenter study the screening will be accomplished using electronic administrative records or in-person screening.

For any eligible patient who screens positive during the study period we will collect data as detailed in the table below:

Day 1 post-hypoxemia detection

  • Demographic characteristics (year of birth, sex, height, weight)
  • Admission data (type of admission - elective/emergency; transfer vs direct admission vs ED admission -; date of admission; if transfer from other hospital; ward - medicine, surgery, ICU)
  • Main diagnosis/clinical presentation
  • Co-morbidities
  • ARDS risk factors at admission
  • New or worsening symptoms within 7 days
  • Institution of mechanical ventilation (invasive or non-invasive)
  • Oxygenation data
  • Lung Ultrasound data
  • CXR and CT scans occurring up to 24 hours before onset of hypoxemia

Day 2-6 post-hypoxemia detection

  • Oxygenation data
  • Lung Ultrasound data
  • Chest imaging

Day 7 post-hypoxemia detection

  • Etiology of hypoxemia (as determined by MRP)
  • New ARDS risk factors identified
  • Need for ICU admission first 7 days
  • Institution of mechanical ventilation first 7 days (invasive and non-invasive)
  • Oxygenation data
  • Lung Ultrasound data
  • Structured focused lung ultrasound
  • Chest imaging

Outcome data collection

  • Vital status at hospital separation, censored at 90 days
  • Date of hospital discharge (or death)
  • ICU admission and duration of ICU stay

For any eligible patient who does not screen positive during any day of the study period (days 1-7 post hospital admission), we will collect the following data:

  • Vital status at hospital separation, censored at 90 days
  • Date of hospital discharge (or death)
  • ICU admission and duration of ICU stay

For patients undergoing CT chest during the 7 days of data collection, we will attempt the performance of an extra lung ultrasound examination immediately before or after the CT scan

Being tested
Estimation of hospital-wide incidence of ARDS
Medical subject headings
Respiratory Insufficiency

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Estimation of hospital-wide incidence of ARDSDiagnostic test

    Estimation of hospital-wide incidence of ARDS defined according to both the Berlin definition and the Kigali modification.

    • To describe clinical characteristics and outcomes for these patients.
    • To analyze the prognosis and time course of patients who initially meet criteria for Kigali-defined ARDS and subsequently progress to Berlin-defined ARDS.

    For the subset of patients who have chest CT, to determine the sensitivity and specificity for bilateral opacities of both chest radiographs and chest ultrasound done within 12 hours as compared to the reference standard CT scans.

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Hospital-wide incidence of ARDS

    ARDS incidence will be calculated as the number of patients fulfilling ARDS (Berlin or Kigali) during the first first 7 days of hospital admission divided by the total adult hospital admissions during the study period.

    Measured: Up to 7 days

Secondary outcomes (1)
  1. Sensitivity and specificity for bilateral opacities of both chest radiographs and chest ultrasound done within 12 hours as compared to the reference standard CT scans

    We will calculate the sensitivity, specificity, positive predictive value and negative predictive value of both chest radiographs and ultrasound images for bilateral opacities not due to effusion, nodule or collapse, as compared with gold standard CT scan when performed.

    Measured: Over the first 7 days of admission

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted6 Jun 2018
  2. Study start24 Oct 2018
  3. Primary completion5 May 2023
  4. Study completion15 Oct 2023 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
9,999 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03546699
Sponsor's protocol ID
LUS01_2018
Status last verified
May 2023
First submitted
17 May 2018
Last updated
11 May 2023
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Undecided

Publications

  • Riviello ED, Kiviri W, Twagirumugabe T, Mueller A, Banner-Goodspeed VM, Officer L, Novack V, Mutumwinka M, Talmor DS, Fowler RA. Hospital Incidence and Outcomes of the Acute Respiratory Distress Syndrome Using the Kigali Modification of the Berlin Definition. Am J Respir Crit Care Med. 2016 Jan 1;193(1):52-9. doi: 10.1164/rccm.201503-0584OC.

    PubMed 26352116

Questions about this trial

What is this clinical trial studying?

An observational study of ARDS and Respiratory Failure, run by University Health Network, Toronto at 4 sites in 3 countries.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 11 May 2023. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 4 sites in Italy, United States, Canada. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Hospital-wide incidence of ARDS (time frame: Up to 7 days). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT03546699, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 11 May 2023.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in